Klotho Neurosciences (KLTO) Competitors $0.59 -0.02 (-3.96%) As of 03:40 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KLTO vs. BTMD, ONCY, ZYBT, ATOS, VIRI, TVGN, OVID, HURA, TIL, and STTKShould you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include biote (BTMD), Oncolytics Biotech (ONCY), Zhengye Biotechnology (ZYBT), Atossa Genetics (ATOS), Virios Therapeutics (VIRI), Tevogen Bio (TVGN), Ovid Therapeutics (OVID), TuHURA Biosciences (HURA), Instil Bio (TIL), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Klotho Neurosciences vs. Its Competitors biote Oncolytics Biotech Zhengye Biotechnology Atossa Genetics Virios Therapeutics Tevogen Bio Ovid Therapeutics TuHURA Biosciences Instil Bio Shattuck Labs biote (NASDAQ:BTMD) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Which has better valuation & earnings, BTMD or KLTO? biote has higher revenue and earnings than Klotho Neurosciences. Klotho Neurosciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$197.19M0.71$3.16M$0.903.15Klotho NeurosciencesN/AN/A-$6.15M-$0.45-1.32 Do institutionals & insiders believe in BTMD or KLTO? 21.7% of biote shares are held by institutional investors. Comparatively, 20.1% of Klotho Neurosciences shares are held by institutional investors. 24.0% of biote shares are held by company insiders. Comparatively, 26.7% of Klotho Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is BTMD or KLTO more profitable? biote has a net margin of 15.73% compared to Klotho Neurosciences' net margin of 0.00%. biote's return on equity of -21.00% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets biote15.73% -21.00% 18.26% Klotho Neurosciences N/A -325.88%-242.15% Does the media favor BTMD or KLTO? In the previous week, Klotho Neurosciences had 2 more articles in the media than biote. MarketBeat recorded 2 mentions for Klotho Neurosciences and 0 mentions for biote. biote's average media sentiment score of 0.70 beat Klotho Neurosciences' score of 0.65 indicating that biote is being referred to more favorably in the media. Company Overall Sentiment biote Positive Klotho Neurosciences Positive Which has more risk & volatility, BTMD or KLTO? biote has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Klotho Neurosciences has a beta of 10.05, suggesting that its stock price is 905% more volatile than the S&P 500. Do analysts recommend BTMD or KLTO? biote currently has a consensus price target of $6.00, indicating a potential upside of 111.64%. Given biote's stronger consensus rating and higher possible upside, research analysts plainly believe biote is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Klotho Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Summarybiote beats Klotho Neurosciences on 12 of the 15 factors compared between the two stocks. Get Klotho Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLTO vs. The Competition Export to ExcelMetricKlotho NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.78M$2.63B$6.11B$10.54BDividend YieldN/A57.78%5.73%4.78%P/E Ratio-1.3222.9684.1027.08Price / SalesN/A760.61608.24131.39Price / CashN/A175.9337.8662.13Price / Book14.855.3212.246.58Net Income-$6.15M$33.06M$3.32B$276.75M7 Day Performance1.61%-1.02%0.73%0.88%1 Month Performance4.23%8.81%7.97%4.10%1 Year Performance-0.88%-4.02%71.13%35.25% Klotho Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLTOKlotho Neurosciences0.4307 of 5 stars$0.59-4.0%N/A+10.1%$41.78MN/A-1.32N/ANews CoverageBTMDbiote2.5299 of 5 stars$2.84-2.4%$6.00+111.3%-46.8%$143.87M$197.19M3.16194ONCYOncolytics Biotech1.6962 of 5 stars$1.35-0.7%$5.00+270.4%-6.4%$136.49MN/A-5.0030ZYBTZhengye BiotechnologyN/A$2.94+2.1%N/AN/A$135.84M$25.53M0.00278News CoverageAnalyst ForecastATOSAtossa Genetics2.624 of 5 stars$1.01+1.0%$6.25+518.8%-29.9%$129.17MN/A-4.398VIRIVirios TherapeuticsN/A$6.69+4.4%$5.00-25.3%+65.3%$128.84MN/A-24.785TVGNTevogen Bio2.8306 of 5 stars$0.74+14.3%$10.00+1,247.9%-30.6%$127.62MN/A-3.903News CoverageOVIDOvid Therapeutics4.1841 of 5 stars$1.67-6.7%$3.10+85.6%+33.1%$127.29M$570K-3.1560HURATuHURA Biosciences1.5524 of 5 stars$2.50+0.4%$12.67+406.7%N/A$127.25MN/A0.00N/ATILInstil Bio3.6938 of 5 stars$18.58+0.8%$88.50+376.3%-50.8%$124.42MN/A-1.44410Positive NewsAnalyst ForecastSTTKShattuck Labs3.3982 of 5 stars$2.45-5.4%$3.00+22.4%+24.1%$124.07M$5.72M-2.02100Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies biote Competitors Oncolytics Biotech Competitors Zhengye Biotechnology Competitors Atossa Genetics Competitors Virios Therapeutics Competitors Tevogen Bio Competitors Ovid Therapeutics Competitors TuHURA Biosciences Competitors Instil Bio Competitors Shattuck Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLTO) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
